文献速递白血病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

分子时代的幼年型粒单核细胞白血病:诊断、危险分层与治疗临床指南

Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment.
PubMed 文献 · Blood Adv · 2021-01-01

本文综述幼年型粒单核细胞白血病(JMML)的临床诊疗进展。该病为婴幼儿期重叠型骨髓增殖/骨髓异常综合征,结局从自发缓解到致命性急性髓系白血病转化不等。二代测序使几乎所有患者获得分子诊断,但大多数仍需异基因造血细胞移植治愈,未来需改进危险分层以区分可观察等待与需快速移植者。

要点

  • JMML是婴幼儿期骨髓增殖与骨髓异常重叠综合征,临床结局高度异质。
  • 二代测序可在几乎所有患者中实现更准确的分子诊断。
  • 多数患者治愈仍依赖异基因造血细胞移植,需改进危险分层区分观察与移植。

核心结论

  • 二代测序使几乎所有JMML患者获得分子诊断,但大多数治愈仍依赖异基因造血细胞移植。
  • 需进一步改进危险分层算法以区分可观察等待与需快速移植的患者。

研究设计与样本

  • 综述类文章,检索范围原文未报告。

主要发现

  • JMML结局从罕见患者自发缓解到其他患者转化为急性髓系白血病且通常致命不等。
  • 二代测序允许在几乎所有患者中进行更准确的分子诊断。

临床怎么用

  • 对JMML患者应结合分子诊断进行危险分层,区分可观察等待与需快速异基因造血细胞移植者。

局限性

  • 原文未报告综述检索范围。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Juvenile myelomonocytic leukemia is an overlapping myeloproliferative and myelodysplastic disorder of early childhood . It is associated with a spectrum of diverse outcomes ranging from spontaneous resolution in rare patients to transformation to acute myeloid leukemia in others that is generally fatal. This unpredictable clinical course, along with initially descriptive diagnostic criteria, led to decades of productive international research. Next-generation sequencing now permits more accurate molecular diagnoses in nearly all patients. However, curative treatment is still reliant on allogeneic hematopoietic cell transplantation for most patients, and additional advances will be required to improve risk stratification algorithms that distinguish those that can be observed expectantly from others who require swift hematopoietic cell transplantation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wintering A, Dvorak CC, Stieglitz E, et al. Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment. Blood Adv. 2021. PMID: 34525182. doi:10.1182/bloodadvances.2021005117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。